{"id":22474,"date":"2025-08-05T18:29:21","date_gmt":"2025-08-05T05:29:21","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=22474"},"modified":"2025-08-05T18:29:21","modified_gmt":"2025-08-05T05:29:21","slug":"zanubrutinib-remains-unfunded-in-new-zealand","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=22474","title":{"rendered":"Zanubrutinib remains unfunded in New Zealand"},"content":{"rendered":"<p>Zanubrutinib has been publicly funded and accessible for the treatment Chronic Lymphocytic Leukaemia (CLL) in Australia for more than two years, offering patients a targeted therapy option with proven efficacy and tolerability.<\/p>\n<p>Its availability across the Tasman highlights the growing disparity in access to innovative blood cancer treatments between Australia and New Zealand.<\/p>\n<p>In light of the Government\u2019s failure to deliver on its pre-election commitment to fund blood cancer medicines, this is a clear priority for advocacy ahead of next year\u2019s general election.<\/p>\n<p>Read more here:\u00a0<a href=\"https:\/\/healthtree.org\/cll\/community\/articles\/zanubrutinib-leads-in-covalent-btk-inhibitors?\" target=\"_blank\" rel=\"noopener\">https:\/\/healthtree.org\/cll\/community\/articles\/zanubrutinib-leads-in-covalent-btk-inhibitors?<\/a><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zanubrutinib has been publicly funded and accessible for the treatment Chronic Lymphocytic Leukaemia (CLL) in Australia for more than two [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":22475,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12,17],"tags":[79,94,95,96,102,105,131],"class_list":["post-22474","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media","category-featured","tag-sam-neil-blood-cancer-pharmac","tag-zanubrutinib-sonrotoclax","tag-ben-schrader-cll-advocates-chronic-lymphocyctic-leukaemia","tag-clinical-trials-cll-blood-cancer","tag-david-seymour-christopher-luxon","tag-dr-malcolm-mulholland","tag-christopher-luxon"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2025\/08\/Drug_Containers.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/22474","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22474"}],"version-history":[{"count":1,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/22474\/revisions"}],"predecessor-version":[{"id":22479,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/22474\/revisions\/22479"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/22475"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22474"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22474"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22474"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}